Tazarotene topical Alternatives Compared
Tazarotene topical | Otezla | Skyrizi |
|
---|
Tazarotene topical | Otezla (apremilast) | Skyrizi (risankizumab) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Tazarotene topical is a retinoid preparation that may be used to treat psoriasis, acne, or photoaging. It is available as a cream, gel, foam, or lotion, and itching, burning, redness, stinging... View more |
Prescription only
Otezla is a PDE4 inhibitor that may be used to treat plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s Disease. It has been associated with severe diarrhea, nausea, and v... View more |
Prescription only
Skyrizi is an interleukin inhibitor that may be used to reduce inflammation-associated plaque psoriasis, psoriatic arthritis, or Crohn's disease in adults. The usual dosage is 150mg every 12 weeks... View more |
||||||||||||||||||||||||
More about Tazarotene topical | More about Otezla (apremilast) | More about Skyrizi (risankizumab) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Tazarotene topical has an average rating of 7.3 out of 10 from a total of 72 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 25% reported a negative effect. |
Otezla has an average rating of 5.1 out of 10 from a total of 431 ratings on Drugs.com. 35% of reviewers reported a positive effect, while 41% reported a negative effect. |
Skyrizi has an average rating of 7.8 out of 10 from a total of 40 ratings on Drugs.com. 73% of reviewers reported a positive effect, while 19% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
See also: tazarotene topical side effects in more detail. |
See also: Otezla side effects in more detail. |
See also: Skyrizi side effects in more detail. |
||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
N/A |
|||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all tazarotene topical prices |
View all Otezla prices |
View all Skyrizi prices |
||||||||||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Arazlo, Avage, Fabior, Tazorac |
N/A |
N/A |
||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
18 hours |
9 hours |
672 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 12 drugs are known to interact with tazarotene topical:
|
A total of 86 drugs are known to interact with Otezla:
|
A total of 170 drugs are known to interact with Skyrizi:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
June 13, 1997 |
March 21, 2014 |
April 23, 2019 |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.